SION
HEALTHCARESionna Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving SION Today?
No stock-specific AI insight has been generated for SION yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$43.29
Fundamentals
Trading
SION News
20 articles- A Look At Sionna Therapeutics (SION) Valuation After Its Strong 1 Year Return And Premium P/B RatioYahoo Finance·May 5, 2026
- Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should WatchThe Motley Fool·Apr 27, 2026
- Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic FibrosisYahoo Finance·Apr 27, 2026
- Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation SymposiumYahoo Finance·Apr 7, 2026
- Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another StoryThe Motley Fool·Mar 31, 2026
- Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?Motley Fool·Mar 18, 2026
- This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on SharesMotley Fool·Mar 15, 2026
- Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 2, 2026
- Assessing Sionna Therapeutics (SION) Valuation As Premium P/B Meets Cooling Share Price MomentumYahoo Finance·Feb 27, 2026
- Sionna Therapeutics to Participate in Upcoming March 2026 Investor ConferencesYahoo Finance·Feb 23, 2026
- Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim SummitMarketbeat·Feb 15, 2026
- Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 4, 2026
- Sionna Therapeutics Chief Legal Officer Caps Off Strong 2025 with Sale of Over 10,000 SharesMotley Fool·Jan 13, 2026
- Assessing Sionna Therapeutics (SION) Valuation After Recent Share Price Swings And Premium P/B MultipleYahoo Finance·Jan 12, 2026
- Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 5, 2026
- A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 MillionMotley Fool·Jan 3, 2026
- Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst callsYahoo Finance·Dec 23, 2025
- Sionna Therapeutics Valuation Topping $2 Billion Is 'Too Optimistic', RBC SaysYahoo Finance·Dec 4, 2025
- Sionna Therapeutics to Participate in Upcoming December Investor ConferencesYahoo Finance·Nov 24, 2025
- Sionna Therapeutics (SION): Assessing Valuation After a Rapid 95% 3-Month Share Price SurgeYahoo Finance·Nov 7, 2025
All 20 articles loaded
Price Data
52-Week Range
$43.29
Fundamentals
Trading
About Sionna Therapeutics Inc
Sionna Therapeutics, Inc. is a pioneering biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases, particularly those characterized by protein misfolding and aggregation, including Alzheimer's and Parkinson's diseases. With a strong emphasis on proprietary technologies and a scientifically robust pipeline, Sionna is addressing critical unmet medical needs in this space. The company's strategic collaborations and commitment to research and development solidify its role as a significant contender in the biopharmaceutical sector, with a mission to enhance patient quality of life through groundbreaking advancements in neurology.